Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$69.00 USD

69.00
2,186,498

-3.33 (-4.60%)

Updated Nov 5, 2024 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks News

Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?

Continued strength in Aurora Cannabis' (ACB) domestic-adult-recreational segment is expected to have driven Q1 sales.

Henry Schein (HSIC) Q3 Earnings Top Estimates, 2021 EPS View Up

Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the third quarter.

Henry Schein (HSIC) Q3 Earnings and Revenues Top Estimates

Henry Schein (HSIC) delivered earnings and revenue surprises of 17.02% and 8.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stock Earnings on Nov 2: IDXX, STE & More

With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.

Is a Surprise Coming for Henry Schein (HSIC) This Earnings Season?

Henry Schein (HSIC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why the Earnings Surprise Streak Could Continue for Henry Schein (HSIC)

Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Urmimala Biswas headshot

4 Medical Products Stocks Poised to Beat This Earnings Season

Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.

BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?

Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q4 sales.

What's in Store for Henry Schein (HSIC) in Q3 Earnings?

Strengthening demand in the global dental and medical markets along with the recent investments are likely to have contributed to Henry Schein's (HSIC) Q3 performance.

Henry Schein (HSIC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SmileDirectClub (SDC) Introduces Two New Water Flossers

SmileDirectClub (SDC) launched the new Large Tank and Compact Water Flossers, currently available at Shop.SmileDirectClub.com, Amazon, Walmart and Walmart.com.

Breast Health Sales to Drive Hologic's (HOLX) Q4 Earnings

The acquisition of Biotheranostics and the launch of new software are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the fourth quarter.

Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?

Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its fourth-quarter performance.

Here's Why You Should Hold on to Walgreens Boots (WBA) for Now

Investors are optimistic about Walgreens Boots (WBA) given its better-than-expected fourth-quarter fiscal 2021 results and strategic alliances.

QIAGEN's (QGEN) New Manchester Facility to Fortify UK Foothold

QIAGEN's (QGEN) new campus is expected to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.

Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?

Recovery in Clinical Diagnostics arm and strong growth in Droplet Digital PCR platform are expected to have contributed to Bio-Rad's (BIO) Q3 results.

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

Continued strong adoption of Invisalign Clear Aligners and iTero scanners is expected to contribute to Align Technology's (ALGN) third-quarter 2021 results.

Insulet's (PODD) Omnipod Sales Grow on New Product Upgrade

Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.

QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets

QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.

ResMed (RMD) to Report Q1 Earnings: What's in the Cards?

Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).

Intuitive Surgical's (ISRG) Ion System Backed by Clinical Study

Latest study results of Intuitive Surgical's (ISRG) Ion system indicate the potential for this technology to help safely biopsy small lung nodules.

Abbott's (ABT) Nutrition Arm in Focus on Real Madrid Alliance

According to Abbott (ABT), the partnership is set to support education, sports and social welfare activities of at-risk children in 80 countries.

Here's Why You Should Retain Allscripts (MDRX) Stock For Now

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and various innovation milestones.

LHC Group (LHCG) Reports Impressive Preliminary Q3 Revenues

Growth in LHC Group's (LHCG) revenues in the third quarter is likely to have been boosted by continued strength in its home health and hospice services.